Abrocitinib Tyrosine-protein kinase JAK1 inhibitor Treatment of atopic dermatitis
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Atopic dermatitis (AD) is one of the most common chronic skin diseases and has an unmet need for effective therapeutic options. Key components in the pathophysiology of AD rely on the JAK-STAT signaling pathway and JAK inhibition has therefore emerged as a promising novel therapeutic strategy. Abrocitinib (PF-04965842) is a JAK1-selective small molecule inhibitor, currently under investigation for the treatment of moderate to severe AD. Phase II and III clinical trials demonstrated a rapid and significant effect of abrocitinib 100 and 200 mg compared to placebo throughout all studies. Abrocitinib was well tolerated with an acceptable safety profile and low rate of serious adverse events and discontinuations due to adverse events. The presented results make abrocitinib a promising addition to the existing therapies for AD.
|Tidsskrift||Drugs of the Future|
|Status||Udgivet - 2021|